Topics

Astellas makes gene therapy a core focus with $3bn Audentes buy

04:52 EST 4 Dec 2019 | PMLIVE

Deal includes a late-stage candidate for a rare disease

Original Article: Astellas makes gene therapy a core focus with $3bn Audentes buy

NEXT ARTICLE

More From BioPortfolio on "Astellas makes gene therapy a core focus with $3bn Audentes buy"

Quick Search